Board names Dr. Daniel Jorgensen as Chief Executive OfficerContinue reading
Category Archives: AZBio News
Anuncia Medical, Inc. Honored with an AZBio Fast Lane Award
Relieving Pressure on the Brain
Cerebrospinal fluid (CSF) normally flows through the cavities (ventricles) of our brains and bathes our brain and spinal column. Hydrocephalus is a condition caused by a buildup of this fluid deep within the brain. The excess fluid puts pressure on the brain. This pressure can damage brain tissues and cause a range of brain function problems. Hydrocephalus can happen at any age, but it occurs more frequently among infants and adults 60 and over.Continue reading
AZBio Kicks of Arizona Bioscience Week on ABC15 (video)
Arizona Bioscience Week has begun. AZBio CEO, Joan Koerber-Walker, kicked things off on ABC15 Arizona and shared highlights of all the exciting things that are happening and how YOU can get connected with Arizona’s Health Innovators.
Check out all of the #AZBW2022 events at https://www.azbio.org/azbw2022 Continue reading
Dr. Brinton Named AZ Bioscience Researcher of the Year

Roberta Diaz Brinton, PhD
Roberta Diaz Brinton, PhD, director of the University of Arizona Center for Innovation in Brain Science(CIBS) will be honored as the Arizona Bioscience Researcher of the Year by the Arizona Bioindustry Association (AZBio) at the 2022 AZBio Awards event Sept. 28 at the Phoenix Convention Center.
Dr. Brinton is a Regents Professor of Pharmacology with an additional appointment in neurology in the UArizona College of Medicine – Tucson and a member of BIO5 Institute. She returned to her alma mater in 2016 to create CIBS, a hybrid university/biotech research center designed to advance cures for Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and amyotrophic lateral sclerosis, or ALS, through integrated discovery, translational and clinical science. Since its inception, CIBS has received more than $112 million in grants to advance cures for these neurodegenerative diseases.Continue reading
Aqualung Therapeutics Corp. Announces FDA Clearance of Investigational New Drug (IND) Application for ALT-100, a Novel mAb Therapy for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
– Aqualung will continue the P1A Healthy Human Volunteer Trial and complete the trial first half of 2023
– The Phase 2A study (PUERTA) will be initiated in the 2nd half of 2023
– ALT-100 is the first humanized mAb therapy that targets the eNAMPT protein which plays a pivotal role in regulating inflammation and fibrosisContinue reading
Deep Proteomic Profiling Reveals Possible Therapeutic Targets for Medulloblastoma
PHOENIX—September 26, 2022—A deep dive into the proteins and protein activities of human tumors grown in mouse models expands the potential therapeutic pathways to treat medulloblastoma, according to a new study published in the Journal of Proteome Research. Continue reading
Phoenix Mayor Kate Gallego honored with AZBio Public Service Award
The path for a cure for cancer will run through Phoenix.
Sit down with Phoenix Mayor Kate Gallego and bring up the subject of biosciences, you will experience a burst of energy and insight about the innovation in healthcare taking place across Phoenix, including the growth of businesses creating jobs, and a personal passion that, “the path for a cure for cancer will run through Phoenix.”Continue reading
BMSEED Awarded Grant to develop a physiologically relevant pre-clinical drug screening platform for Alzheimer’s Disease and Traumatic Brain Injury
New Microfluidics Platform with embedded Stretchable Microelectrodes for Research on Alzheimer’s Disease and other Neurological and Neurodegenerative DiseasesContinue reading
Exact Sciences Awards Grants To Federally Qualified Health Centers Focused On Improving Colorectal Cancer Screening Of Vulnerable Populations
MADISON, Wis., Sept. 22, 2022 — Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today awarded $525,000 in grants to eight federally qualified health centers focused on improving colorectal cancer screening rates in vulnerable populations.Continue reading
Vidium Animal Health® SearchLight DNA® Added to Antech Diagnostics® Portfolio of Tests Expanding Veterinarians’ Ability to Diagnose and Treat Cancer in Dogs
PHOENIX—September 22, 2022—Vidium Animal Health announced today that it has entered a reseller agreement with Antech Diagnostics to provide SearchLight DNAⓇ, the best-in-class genomic diagnostic for cancer in dogs, to Antech’s large North American customer base. Genomic diagnostics in general, and SearchLight DNA in particular, are a key part of expanding the use of personalized medicine in canine patients.
Continue reading